ARTICLE | Company News
Biotest, ImmunoGen deal
July 17, 2006 7:00 AM UTC
BIO received exclusive rights to use IMGN's tumor-activated prodrug (TAP) technology with antibodies against an undisclosed target to treat multiple myeloma (MM) and other cancers. IMGN will receive $...